Prothrombin 20210G>A is an ancestral prothrombotic mutation that occurred in whites approximately 24 000 years ago

Blood

Volumn 107, Issue 12, 2006, Pages 4666-4668

  Zivelin, Ariella ^b   Mor Cohen, Ronit ^b   Kovalsky, Victoria ^b   Kornbrot, Nurit ^b   Conard, Jacqueline ^b   Peyvandi, Flora ^b   Kyrle, Paul A ^b   Bertina, Rogier ^b   Peyvandi, Ferial ^b   Emmerich, Joseph ^b   Seligsohn, Uri ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; MICROSATELLITE DNA; PROTHROMBIN; PROTHROMBIN 20210A; PROTHROMBIN 20210G; UNCLASSIFIED DRUG;

ARTICLE; BLEEDING; DNA DETERMINATION; ETHNIC DIFFERENCE; ETHNOLOGY; EUROPEAN AMERICAN; GENE; GENE LINKAGE DISEQUILIBRIUM; GENE MUTATION; GENETIC ANALYSIS; HOMOZYGOTE; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33745105401     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2005-12-5158     Document Type: Article

References (20)

1. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
2. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls: Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001;86:809-816.
3. Gehring NH, Frede U, Neu-Yilik G, et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet. 2001;28:389-392.
4. Ceelie H, Spaargaren-van Riel CC, Bertina RM, Vos HL. G20210A is a functional mutation in the prothrombin gene: effect on protein levels and 3′-end formation. J Thromb Haemost. 2004;2:119-127.
5. Rees DC, Chapman NH, Webster MT, Guerreiro JF, Rochette J, Clegg JB. Born to clot: the European burden. Br J Haematol. 1999;105:564-566.
6. Zivelin A, Rosenberg N, Faier S, et al. A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene. Blood. 1998;92:1119-1124.
7. National Center for Biotechnology Information. NCBI SNP database. http://www.ncbi.nlm.nih. gov. Accessed April 14, 2006.
8. Rannala B, Reeve JP. High-resolution multipoint linkage-disequilibrium mapping in the context of a human genome sequence. Am J Hum Genet. 2001;69:159-178.
9. Reeve JP, Rannala B. DMLE+: Bayesian linkage disequilibrium gene mapping. Bioinformatics. 2002;18:894-895.
10. Pritchard JK, Seielstad MT, Perez-Lezaun A, Feldman MW. Population growth of human Y chromosomes: a study of Y chromosome microsatellites. Mol Biol Evol. 1999;16:1791-1798.
11. Population Reference Bureau. 2005 World Population Data Sheet of the Population Reference Bureau. http://www.prb.org/pdf05/05World DataSheet_Eng.pdf. Accessed April 14, 2006.
12. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79:706-708.
13. Zivelin A, Griffin JH, Xu X, et al. A single genetic origin for a common Caucasian risk factor for venous thrombosis. Blood. 1997;89:397-402.
14. Seligsohn U, Zivelin A. Thrombophilia as a multigenic disorder. Thromb Haemost. 1997;78:297-301.
15. Irani-Hakime N, Tamim H, Kreidy R, Almawi WY. The prevalence of factor V R506Q mutation-Leiden among apparently healthy Lebanese. Am J Hematol. 2000;65:45-49.
16. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss: a possible evolutionary selection mechanism. Thromb Haemost. 1998;79:69-73.
17. Lindqvist PG, Zoller B, Dahlback B. Improved hemoglobin status and reduced menstrual blood loss among female carriers of factor V Leiden: an evolutionary advantage? Thromb Haemost. 2001;86:1122-1123.
18. Kerlin BA, Yan SB, Isermann BH, et al. Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood. 2003;102:3085-3092.
19. Yan SB, Nelson DR. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Crit Care Med. 2004;32:S239-S246.
20. Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A. Influence of the factor V leiden mutation on infectious disease susceptibility and outcome: a population-based study. J Infect Dis. 2005;192:1851-1857.